Last reviewed · How we verify
MYL- 1401O
MYL-1401O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to prevent tumor angiogenesis.
MYL-1401O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to prevent tumor angiogenesis. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | MYL- 1401O |
|---|---|
| Also known as | Hercules |
| Sponsor | Mylan Inc. |
| Drug class | Monoclonal antibody (bevacizumab biosimilar) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a bevacizumab biosimilar, MYL-1401O binds to and neutralizes VEGF, a key signaling protein that promotes the formation of new blood vessels supplying tumors. By blocking VEGF, the drug starves tumors of their blood supply, slowing or halting tumor growth. This mechanism is used across multiple solid tumor indications where angiogenesis is a critical driver of progression.
Approved indications
- Metastatic colorectal cancer
- Non-squamous non-small cell lung cancer
- Metastatic breast cancer
- Renal cell carcinoma
Common side effects
- Hypertension
- Proteinuria
- Bleeding/hemorrhage
- Thromboembolic events
- Gastrointestinal perforation
- Wound healing complications
Key clinical trials
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study (PHASE2)
- Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |